ATE313538T1 - Chinolin-4-ylderivate und ihre verwendung als nmda-rezeptor subtyp blocker - Google Patents
Chinolin-4-ylderivate und ihre verwendung als nmda-rezeptor subtyp blockerInfo
- Publication number
- ATE313538T1 ATE313538T1 AT00121561T AT00121561T ATE313538T1 AT E313538 T1 ATE313538 T1 AT E313538T1 AT 00121561 T AT00121561 T AT 00121561T AT 00121561 T AT00121561 T AT 00121561T AT E313538 T1 ATE313538 T1 AT E313538T1
- Authority
- AT
- Austria
- Prior art keywords
- quinoline
- derivatives
- nmda receptor
- receptor subtype
- subtype blockers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99120131 | 1999-10-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE313538T1 true ATE313538T1 (de) | 2006-01-15 |
Family
ID=8239160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00121561T ATE313538T1 (de) | 1999-10-08 | 2000-10-02 | Chinolin-4-ylderivate und ihre verwendung als nmda-rezeptor subtyp blocker |
Country Status (26)
Country | Link |
---|---|
US (1) | US6339093B1 (de) |
EP (1) | EP1090917B1 (de) |
JP (1) | JP3385318B2 (de) |
KR (1) | KR100398562B1 (de) |
CN (1) | CN1162424C (de) |
AR (1) | AR032601A1 (de) |
AT (1) | ATE313538T1 (de) |
AU (1) | AU777881B2 (de) |
BR (1) | BR0004709A (de) |
CA (1) | CA2322309C (de) |
DE (1) | DE60024947T2 (de) |
DK (1) | DK1090917T3 (de) |
EG (1) | EG23872A (de) |
ES (1) | ES2254095T3 (de) |
HR (1) | HRP20000652A2 (de) |
HU (1) | HUP0003938A2 (de) |
ID (1) | ID27526A (de) |
IL (1) | IL138916A0 (de) |
MA (1) | MA26753A1 (de) |
MX (1) | MXPA00009771A (de) |
NO (1) | NO20005031L (de) |
NZ (1) | NZ507303A (de) |
PE (1) | PE20010660A1 (de) |
PL (1) | PL343057A1 (de) |
TR (1) | TR200002893A3 (de) |
ZA (1) | ZA200005447B (de) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6339093B1 (en) * | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
US7375136B2 (en) * | 2001-03-08 | 2008-05-20 | Emory University | pH-dependent NMDA receptor antagonists |
US6831087B2 (en) * | 2001-11-09 | 2004-12-14 | Hoffmann-La Roche Inc. | Pyridine substituted isoquinoline derivatives |
US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
US8110681B2 (en) | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
PT2167469E (pt) * | 2007-06-18 | 2012-11-20 | Richter Gedeon Nyrt | Derivados de sulfonil-quinoleína |
US8420680B2 (en) * | 2007-06-29 | 2013-04-16 | Emory University | NMDA receptor antagonists for neuroprotection |
CA2700841A1 (en) * | 2007-09-27 | 2009-04-02 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
JP6969800B2 (ja) * | 2016-05-04 | 2021-11-24 | ジェノシアンス ファルマ | 増殖性疾患の治療に使用される置換2,4−ジアミノ−キノリン誘導体 |
EP3558318B1 (de) | 2016-12-22 | 2023-12-20 | Novartis AG | Nmda-rezeptor-modulatoren und verwendungen davon |
IL280474B2 (en) | 2018-08-03 | 2023-09-01 | Cadent Therapeutics Inc | Heteroaromatic nmda receptor modulators and their uses |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8409745D0 (en) * | 1984-04-14 | 1984-05-23 | Beecham Group Plc | Active compounds |
US4560692A (en) * | 1984-07-18 | 1985-12-24 | Hoffmann-La Roche Inc. | 4-Piperidino-2-phenylquinolines |
GB8716972D0 (en) * | 1987-07-17 | 1987-08-26 | Pfizer Ltd | Treatment of cardiac arrhythmias |
JPH0262875A (ja) | 1988-05-23 | 1990-03-02 | Wakunaga Pharmaceut Co Ltd | 新規イソインドリン誘導体 |
US4992448A (en) * | 1989-10-24 | 1991-02-12 | Hoechst-Roussel Pharmaceuticals Inc. | Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders |
US5304554A (en) * | 1990-04-27 | 1994-04-19 | Emory University | 4-[(alkyl or dialkyl)amino]quinolines and their method of preparation |
GB9203798D0 (en) * | 1992-02-21 | 1992-04-08 | Fujisawa Pharmaceutical Co | Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same |
GB9305644D0 (en) * | 1993-03-18 | 1993-05-05 | Merck Sharp & Dohme | Therapeutic agents |
US5567718A (en) * | 1994-08-11 | 1996-10-22 | Hoechst Marion Roussel Inc. | 2,3-dihydro-1h-isoindole derivatives and their use as serotonin reuptake inhibitors |
ZA9610738B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
US6339093B1 (en) * | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
-
2000
- 2000-09-26 US US09/669,648 patent/US6339093B1/en not_active Expired - Fee Related
- 2000-09-29 CN CNB001290843A patent/CN1162424C/zh not_active Expired - Fee Related
- 2000-10-02 DK DK00121561T patent/DK1090917T3/da active
- 2000-10-02 EP EP00121561A patent/EP1090917B1/de not_active Expired - Lifetime
- 2000-10-02 ES ES00121561T patent/ES2254095T3/es not_active Expired - Lifetime
- 2000-10-02 DE DE60024947T patent/DE60024947T2/de not_active Expired - Lifetime
- 2000-10-02 AT AT00121561T patent/ATE313538T1/de not_active IP Right Cessation
- 2000-10-03 PE PE2000001045A patent/PE20010660A1/es not_active Application Discontinuation
- 2000-10-03 NZ NZ507303A patent/NZ507303A/xx unknown
- 2000-10-03 HR HR20000652A patent/HRP20000652A2/hr not_active Application Discontinuation
- 2000-10-04 CA CA002322309A patent/CA2322309C/en not_active Expired - Fee Related
- 2000-10-04 ID IDP20000858D patent/ID27526A/id unknown
- 2000-10-04 TR TR2000/02893A patent/TR200002893A3/tr unknown
- 2000-10-04 JP JP2000304354A patent/JP3385318B2/ja not_active Expired - Fee Related
- 2000-10-04 MA MA26080A patent/MA26753A1/fr unknown
- 2000-10-04 EG EG20001265A patent/EG23872A/xx active
- 2000-10-05 AR ARP000105238A patent/AR032601A1/es not_active Application Discontinuation
- 2000-10-05 IL IL13891600A patent/IL138916A0/xx unknown
- 2000-10-05 MX MXPA00009771A patent/MXPA00009771A/es active IP Right Grant
- 2000-10-05 ZA ZA200005447A patent/ZA200005447B/xx unknown
- 2000-10-06 BR BR0004709-0A patent/BR0004709A/pt not_active Application Discontinuation
- 2000-10-06 AU AU64100/00A patent/AU777881B2/en not_active Ceased
- 2000-10-06 HU HU0003938A patent/HUP0003938A2/hu unknown
- 2000-10-06 NO NO20005031A patent/NO20005031L/no not_active Application Discontinuation
- 2000-10-07 KR KR10-2000-0059049A patent/KR100398562B1/ko not_active IP Right Cessation
- 2000-10-09 PL PL00343057A patent/PL343057A1/xx not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69925730D1 (de) | 4-benzyl-piperidin-alkylsulfoxid-heterozyklen und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten | |
DE60015296D1 (de) | Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten | |
ATE279396T1 (de) | Imidazolderivate und ihre verwendung als somatostatin rezeptorliganden | |
ATE375987T1 (de) | Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel | |
ATE394401T1 (de) | Diazabicycloderivate als nikotin-acetylcholin- rezeptorliganden | |
DE60001840D1 (de) | Chinuclidin-derivate und deren verwendung als muscarin-m3-rezeptoren-liganden | |
ATE250035T1 (de) | Chinolin- und chinazolin-derivate als crf antagonisten | |
DE60112607D1 (de) | 3-arylindolderivate und deren verwendung als cb2-rezeptoragonisten | |
ATE369368T1 (de) | Indolderivate und deren verwendung als 5-ht2b- und 5-ht2c-rezeptorliganden | |
DE60029007D1 (de) | Quinazolin-derivate als vegf-hemmer | |
DE60006580D1 (de) | Benzazolderivate und ihre verwendung als jnk modulatoren | |
DE60106607D1 (de) | Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten | |
DE60135239D1 (de) | Indolinderivate und deren verwendung als 5-ht2 rezeptor liganden | |
DE60023167D1 (de) | Pyrazol-derivate als cannabinoidrezeptor-antagonisten | |
DE60026379D1 (de) | Abstimmbares hochtemperatursupraleitendes filter | |
DE60008262D1 (de) | Piperazinderivate als 5-ht1b antagonisten | |
ATE313538T1 (de) | Chinolin-4-ylderivate und ihre verwendung als nmda-rezeptor subtyp blocker | |
DK0922034T3 (da) | Tetrahydroquinolinderivater som EAA-antagonister | |
DE69816290D1 (de) | Chinolin-4-carboxamidderivate als nk-2 und nk-3 rezeptor antagonisten | |
ATE254621T1 (de) | Thienoisoxazolyl- und thienylpyrazolyl-phenoxy substituierte propyl derivate als d4 antagonisten | |
ATE264315T1 (de) | Aminothiazolderivate und ihre verwendung als crf- rezeptor-liganden | |
ATE395333T1 (de) | 4-phenylpiperazinyl, -piperidinyl und - tetrahydropyridyl-derivate als dopamin d4- antagonisten | |
ATE293619T1 (de) | Pyridinderivate als nmda-rezeptorliganden | |
DE50008020D1 (de) | Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten | |
ATE353325T1 (de) | 4-heterocyclylsulfonamidyl-6-methoxy-5-(2-metho y-phenoxy)-2-pyridyl-pyrimidin derivate, deren herstellung und deren verwendung als endothelin rezeptor antagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1090917 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |